Pharming Group NV has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of experience in the life sciences industry, having previously held finance leadership roles at Schoeller Allibert, Zentiva, Affidea, and Gilead Sciences. His appointment follows strong first half 2025 financial results and is part of Pharming's strategy to strengthen financial leadership as the company continues its growth trajectory.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001125782-en) on September 02, 2025, and is solely responsible for the information contained therein.